Clinical trial · Observational
Long-term Effects of Breast Cancer Treatment
Long-term Effects Following Treatment of Women With Screen-detected Versus Symptomatic Breast Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The objective of this project is to generate evidence about quality of life related to side effects of treatment of women with screen-detected versus symptomatic breast cancer. The project will investigate the impact of detection mode (by screening or by symptoms) versus tumor characteristics as a predictor of quality of life among breast cancer survivors. The burden of long-term effects, measured as quality of life at specific points after diagnosis, will be compared between these groups. The results will also be compared with a control group of women, who have attended screening, but never been diagnosed with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Study II
- description
- * Women with a screen-detected breast cancer after attending BreastScreen Norway * Women with symptomatic breast cancer, who have never been screened in BreastScreen Norway * Women with interval breast cancer after attending BreastScreen Norway * Women free from breast cancer
- label
- Study III
- description
- * Women with a screen-detected breast cancer after attending BreastScreen Norway * Women with interval breast cancer after attending BreastScreen Norway and women with symptomatic breast cancer, who have never been screened in BreastScreen Norway
Primary outcomes (2)
- measure
- Quality of life score
- timeFrame
- 2006-2017
- description
- Quality of life measure from 0 to 100 on a visual analogue scale
- measure
- QALY (Quality-Adjusted-Life-Year)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 50 Years
- Maximum age
- 69 Years
Show eligibility criteria text
Study II Inclusion Criteria: * Screened in BreastScreen Norway and diagnosed with breast cancer between 2006 and 2017 * Diagnosed with symptomatic breast cancer between 2006 and 2017 and never attended screening * Screened in BreastScreen Norway and diagnosed with interval breast cancer between 2006 and 2017 * Screened in BreastScreen Norway and have never been diagnosed with breast cancer Exclusion Criteria: * Death after recruitment Study III Inclusion Criteria: * Screened in BreastScreen Norway and diagnosed with breast cancer between 2006 and 2017 * Screened in BreastScreen Norway and diagnosed with interval breast cancer between 2006 and 2017 * Diagnosed with symptomatic breast cancer between 2006 and 2017 and never attended screening Exclusion Criteria: * Death after recruitment
References
Publications (3)
- RESULTMoshina N, Falk RS, Botteri E, Larsen M, Akslen LA, Ursin G, Cairns JA, Hofvind S. Long-term quality of life and quality adjusted life years after breast cancer: Impact of detection mode, tumor characteristics and treatment. J Cancer Policy. 2025 Sep;45:100631. doi: 10.1016/j.jcpo.2025.100631. Epub 2025 Aug 5. PMID 40774379
- RESULTMoshina N, Falk RS, Botteri E, Larsen M, Akslen LA, Cairns JA, Hofvind S. Quality of life among women with symptomatic, screen-detected, and interval breast cancer, and for women without breast cancer: a retrospective cross-sectional study from Norway. Qual Life Res. 2022 Apr;31(4):1057-1068. doi: 10.1007/s11136-021-03017-7. Epub 2021 Oct 26. PMID 34698976
- RESULTMoshina N, Falk RS, Hofvind S. Long-term quality of life among breast cancer survivors eligible for screening at diagnosis: a systematic review and meta-analysis. Public Health. 2021 Oct;199:65-76. doi: 10.1016/j.puhe.2021.08.008. Epub 2021 Sep 21. PMID 34560477